NASDAQ:OPK - Opko Health Stock Price, Forecast & News

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Opko Health Inc. (NASDAQ:OPK) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The biotechnology company earned $228.80 million during the quarter, compared to analysts' expectations of $225.40 million. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The company's revenue was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.05) earnings per share. View Opko Health's Earnings History.

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

2 analysts have issued 12-month price targets for Opko Health's shares. Their forecasts range from $2.50 to $4.00. On average, they expect Opko Health's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Price Targets for Opko Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

Press coverage about OPK stock has trended extremely negative on Friday, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opko Health earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Opko Health.

Opko Health saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 80,770,000 shares, an increase of 5.5% from the December 31st total of 76,560,000 shares. Based on an average trading volume of 5,380,000 shares, the short-interest ratio is presently 15.0 days. Approximately 20.2% of the shares of the stock are short sold. View Opko Health's Current Options Chain.

Some companies that are related to Opko Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), NVIDIA (NVDA), Novavax (NVAX), AT&T (T) and Bausch Health Companies (BHC).

Opko Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.69%), Geode Capital Management LLC (0.90%), Oracle Investment Management Inc. (0.66%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.45%), Marshall Wace LLP (0.38%) and Farallon Capital Management LLC (0.38%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

OPK stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Bank of Montreal Can, X Square Capital LLC, Connor Clark & Lunn Investment Management Ltd., Rafferty Asset Management LLC, Cito Capital Group LLC, Prudential Financial Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for Opko Health.

OPK stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, Farallon Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Geode Capital Management LLC and Jane Street Group LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPK stock can currently be purchased for approximately $1.62.

Opko Health has a market capitalization of $1.08 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.

The official website for Opko Health is http://www.opko.com/.

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]